Statins: Adverse reactions, oxidative stress and metabolic interactions
A Liu, Q Wu, J Guo, I Ares, JL Rodríguez… - Pharmacology & …, 2019 - Elsevier
Abstract Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are currently
the most effective lipid-lowering drugs, effectively reducing the plasma total cholesterol and …
the most effective lipid-lowering drugs, effectively reducing the plasma total cholesterol and …
2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
[HTML][HTML] Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
A Gupta, MV Madhavan, TJ Poterucha… - Nature …, 2021 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state,
leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic …
leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic …
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial
INSPIRATION-S Investigators - bmj, 2022 - bmj.com
Objective To assess the effect of statin treatment versus placebo on clinical outcomes in
patients with covid-19 admitted to the intensive care unit (ICU). Design INSPIRATION …
patients with covid-19 admitted to the intensive care unit (ICU). Design INSPIRATION …
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients
Aim Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-
hospital mortality. Methods and results Retrospective observational study. Patients taking …
hospital mortality. Methods and results Retrospective observational study. Patients taking …
Racial, ethnic and regional differences in the effect of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and …
Objectives The cardiorenal protective effects of sodium–glucose co-transporter 2 inhibitors
(SGLT2-Is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) across racial and …
(SGLT2-Is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) across racial and …
Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation
E Allara, G Morani, P Carter, A Gkatzionis… - Circulation: Genomic …, 2019 - Am Heart Assoc
Background: Evidence from randomized trials has shown that therapies that lower LDL (low-
density lipoprotein)-cholesterol and triglycerides reduce coronary artery disease (CAD) risk …
density lipoprotein)-cholesterol and triglycerides reduce coronary artery disease (CAD) risk …
Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: A systematic review …
BACKGROUND Traditional diabetes self-monitoring of blood glucose (SMBG) involves
inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned …
inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned …
The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism
NA Marston, Y Gurmu, GEM Melloni, M Bonaca… - Circulation, 2020 - Am Heart Assoc
Background: The relationship between cholesterol levels and risk of venous
thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 …
thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 …